[SMLE] Lambert-Eaton Myasthenic Syndrome Recurrence Induced by Pembrolizumab in a Patient with Non-small-cell Lung Cance

[RSS-Bot]

Intern Med. 2022 Aug 30. doi: 10.2169/internalmedicine.0072-22. Online ahead of print.

ABSTRACT

A 73-year-old woman in complete remission from localized small-cell lung cancer associated with Lambert-Eaton myasthenic syndrome (LEMS) 22 years earlier was referred to our hospital and diagnosed with non-small-cell lung cancer. After three courses of pembrolizumab, an immune checkpoint inhibitor, the patient complained of muscle weakness, fatigue, ptosis, and dysarthria. The anti-voltage-gated calcium channel antibody level was elevated, and waxing was observed on a high-frequency repetitive stimulation test using an electromyogram. We diagnosed her with recurrence of LEMS as an immune-related adverse event (irAE) induced by pembrolizumab. After intravenous immunoglobulin therapy, the patient's symptoms improved, and she was discharged.

PMID:36047125 | DOI:10.2169/internalmedicine.0072-22


Source: https://pubmed.ncbi.nlm.nih.gov/3604712 ... 1&v=2.17.7